Tectonic Therapeutics TECX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.87M+60.1% | $16.34M+78.5% | $16.93M+18.2% | $17.19M+143% | $13.04M+20.5% | ||
| $6.43M+22.2% | $5.18M+7.0% | $4.96M-6.7% | $5.15M+18.4% | $5.26M+145% | ||
| $27.3M+49.2% | $21.52M+53.8% | $21.89M+11.5% | $22.33M+95.5% | $18.3M+41.1% | ||
| $27.3M+49.2% | $21.52M+53.8% | $21.89M+11.5% | $22.33M+95.5% | $18.3M+41.1% | ||
| -$27.3M-49.2% | -$21.52M-53.8% | -$21.89M-11.5% | -$22.33M-95.5% | -$18.3M-41.1% | ||
| $8K-60.0% | $12K-45.5% | $14K-44.0% | $17K-39.3% | $20K-35.5% | ||
| $2.18M-10.8% | $2.56M+47.8% | $2.9M+48.6% | $3.39M+966% | $2.44M+855% | ||
| $2.06M-13.9% | $2.54M+57.2% | $2.86M+48.7% | $3.32M+366% | $2.39M+206% | ||
| —— | -$18.97M-53.3% | -$19.04M-7.4% | -$19.01M-50.0% | -$15.91M-4.5% | ||
| $25.2M+58.4% | $254K— | $0— | $976K— | $15.91M+4.2% | ||
| -$25.24M-58.7% | -$19.23M-55.4% | -$19.04M-7.4% | -$19.98M-57.7% | -$15.91M-4.5% | ||
| -$1.34-44.1% | -$1.03— | -$1.02+15.0% | -$1.07+75.3% | -$0.93+91.5% | ||
| -$1.34-44.1% | -$1.03— | -$1.02+15.0% | -$1.07+75.3% | -$0.93+91.5% | ||
| 18.8M+9.4% | 18.3M+116% | 18.7M+27.0% | 18.7M+540% | 17.2M+1,137% | ||
| 18.8M+9.4% | 18.3M+116% | 18.7M+27.0% | 18.7M+540% | 17.2M+1,137% | ||
| $37K+629% | -$21K-128% | -$26K-62.5% | -$51K-538% | -$7K+86.0% | ||
| $25.2M+58.4% | $19.25M+56.5% | $19.06M+7.5% | $20.04M+58.0% | $15.91M+4.2% | ||
| -$113K-253% | -$8K+91.6% | -$31K-343% | -$48K-860% | -$32K+92.1% | ||
| -$27.3M-49.2% | -$21.52M-53.8% | -$21.89M-11.5% | -$22.33M-95.5% | -$18.3M-41.1% | ||
| -$27M-50.5% | -$21.18M-57.1% | -$21.55M-12.2% | -$21.99M-98.4% | -$17.94M-42.5% | ||
| -$27M-50.5% | -$21.18M-57.1% | -$21.55M-12.2% | -$21.99M-98.4% | -$17.94M-42.5% | ||
| -$27.3M-49.2% | -$21.52M-53.8% | -$21.89M-11.5% | -$22.33M-95.5% | -$18.3M-41.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Tectonic Therapeutics profitable?
- Tectonic Therapeutics is not currently profitable: it reported a net loss of $83.5M over the trailing twelve months.
- What is Tectonic Therapeutics's earnings per share?
- Tectonic Therapeutics's diluted EPS over the trailing twelve months is $-4.46.
- Where does Tectonic Therapeutics's income statement data come from?
- Every line is extracted from Tectonic Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.